Colombia Threatens to Override Novartis's Patent on Gleevec - Wall Street Journal
Wall Street JournalColombia Threatens to Override Novartis's Patent on GleevecWall Street JournalThe government says it plans to make the drug—marketed as Gleevec or Glivec for use against leukemia—available at a cheaper price, with or without the consent of Novartis, despite what the Health Ministry says has been international pressure against .
Clock is ticking on CL deal for Novartis' Gleevec - FiercePharma
FiercePharmaClock is ticking on CL deal for Novartis' GleevecFiercePharmaNovartis ($NVS) has agreed to work with Colombia to lower the price of its cancer drug, Gleevec, to prevent the country from issuing a compulsory license for the med.
Leaked letters show trade tensions over Colombian CL for Novartis' Gleevec - FiercePharma
FiercePharmaLeaked letters show trade tensions over Colombian CL for Novartis' GleevecFiercePharmaTwo leaked letters written by a representative of the Embassy of Colombia in Washington, DC, and sent to officials in that country showcase deep tensions over a plan by the government there to issue a compulsory license and allow generic knockoffs of .
New Novartis meds help relieve Gleevec generics pain - FiercePharma
FiercePharmaNew Novartis meds help relieve Gleevec generics painFiercePharmaIt's accentuate-the-positive time at Novartis.
Colombia Fears U.S. May Reject Peace Plan To Protect Pharma Profits - Huffington Post